Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Childrens Oncology Group Study AALL0232 [Pediatric Oncology]
Conclusion
High-dose methotrexate is superior to Capizzi methotrexate for the treatment of high-risk B-acute lymphoblastic leukemia, with no increase in acute toxicity. Dexamethasone given during induction benefited younger children but provided no benefit and was associated with a higher risk of osteonecrosis among participants 10 years and older.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Larsen, Devidas, Chen, Salzer, Raetz, Loh, Mattano, Cole, Eicher, Haugan, Sorenson, Heerema, Carroll, Gastier-Foster, Borowitz, Wood, Willman, Winick, Hunger, Carroll Tags: Acute Lymphoblastic Leukemia Pediatric Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer & Oncology | Children | Dexamethasone | Leukemia | Methotrexate | Pediatrics | Prednisone | Study | Toxicology